Fact CheckerSign in

NCT07703826Not yet recruiting

Identification of Genes of Interest for Severe Forms of Preeclampsia

Identification of Genes of Interest for Severe Forms of Preeclampsia in a Cohort of Pregnant Women With a Precise Phenotype

Source: ClinicalTrials.gov · Last updated 14 Jul 2026

Brief summary (registry, in English)

Preeclampsia is a pregnancy complication characterized by high blood pressure associated with damage to various organs, especially the kidneys. It happens in about 1 to 5% of pregnant women and can cause serious problems for both the mother and the baby. Several multi-omics studies have already been conducted on preeclampsia, with promising results. However, this is preliminary data that requires further studies. The molecular markers identified in this type of study could potentially be used, first of all, for the early screening of this condition, which is not yet reliably achievable. In addition, the knowledge gained from this research would help us better understand the pathophysiology of preeclampsia. Therefore, the investigators' goal is to carry out a multi-omics analysis of preeclampsia to uncover the genetic and molecular mechanisms involved in this condition.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
9 Jul 2026
Start date
1 Sept 2026
Primary completion date
1 Sept 2029
Lead sponsor
University Hospital, Strasbourg, France
NCT number
NCT07703826

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 1 Sept 2026 to the primary completion date, 1 Sept 2029
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Diabetes prior to pregnancy
  • Long-term medication treatment (except usual pregnancy supplements)
  • Smoking, alcohol, or drug use during pregnancy

Other illness

  • Pre-existing liver, kidney, or heart failure
  • History of bariatric surgery

Other

  • Multiple pregnancy
  • Neonatal acidosis with arterial cord pH below 7.0 (rare event)
  • Genetic or chromosomal abnormality of the mother and/or newborn diagnosed prenatally
  • Fetal malformation diagnosed prenatally
  • Refusal to participate in the study
  • Person unable to consent or under protection (guardianship, curatorship)
  • Minor
  • Inability to participate in the entire study

Who the study is looking for

  • \- Pregnant women between 18 and 45 years old, between 24 and 41 weeks of amenorrhea (WA), with severe preeclampsia defined according to the criteria of the joint expert recommendations of the French National College of Gynecologists and Obstetricians (CNGOF) and the French Society of Anesthesia and Intensive Care (SFAR) from 2020 "Management of the patient with severe preeclampsia." These criteria are: gestational hypertension with systolic ≥ 140 mmHg and/or diastolic ≥ 90 mmHg, and proteinuria ≥ 0.3g/24h, plus at least one of the following severity criteria:
  • Severe hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 110 mmHg) or uncontrolled.
  • Proteinuria \> 3g/24h.
  • Creatinine ≥ 90 μmol/L.
  • Oliguria ≤ 500 mL/24h or ≤ 25 mL/h.
  • Thrombocytopenia \< 100,000/mm3
  • Liver enzyme elevation with AST/ALT \>2x normal.
  • Epigastric abdominal pain and/or persistent or severe right upper quadrant pain "like a band."
  • Chest pain, shortness of breath, acute pulmonary edema.
  • Neurological signs: severe headaches not responding to treatment, persistent visual or auditory disturbances, hyperactive, widespread, and polykinetic tendon reflexes.
  • Patient's free and informed consent regarding the collection of maternal blood and urine.
  • Consent from both legal guardians regarding the collection of cord blood, placenta samples, and newborn data.
  • Pregnant women between 18 and 45 years old and between 24 and 41 weeks of gestation, with a pregnancy without any complications
  • Free and informed consent from the patient regarding the collection of maternal blood and urine
  • Consent from both holders of parental authority regarding the collection of cord blood, placental fragments, and newborn data

Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.